ClinicalTrials.gg
WithdrawnNCT00869856SWEEPUpdated Jun 2, 2015

Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)

A Phase 3 interventional study of HX575 solution for s.c. administration in Anemia and Chronic Renal Insufficiency, sponsored by Sandoz. Withdrawn at 19 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-02.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was withdrawn
investigation of adverse events in a related clinical study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.

Enrollment
106th of 112
0 · median 71
Started
2009
with 2 others
Phase 3
45 of 126
1 open now
Registered
104th of 126
by date
Lead sponsor
3 of 126
Sandoz

Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 106th largest by enrollment of the 112 interventional ones that give a count, is one of 3 that started in 2009, is one of 45 in phase 3, and was the 104th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing Epoetin Alfa in Anemia, or all of them as a file.
02

Study summary

This is an open-label, single-arm, baseline-controlled, multicenter efficacy and safety switch study involving 500 CKD subjects suffering from anemia and treated previously with a stable dose of ESA s.c.

Correction of anemia will be maintained by s.c. administration of HX575 in two frequencies (i.e. qw and q2w), in order to maintain an Hb target range of 10.0-12.0 g/dL.

03

Conditions studied

  • Anemia
  • Chronic Renal Insufficiency

Keywords

  • Treatment associated with CRI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female CKD subjects with or without dialysis treatment
  • Age > 18 years
  • Subjects under documented stable maintenance therapy with ESA, s.c. at least once per week and in accordance with the relevant SmPC, for at least 3 months with a total weekly dose of ≤ 300 IU/kg/week
  • Subjects with controlled symptomatic anemia, defined as mean level between 10.0 g/dL and 12.0 g/dL, based on four Hb measurements during the four-week baseline period
  • Adequate iron status, serum ferritin ≥ 100 µg/L or transferrin saturation ≥ 20%
  • Confirmed negative anti-EPO antibody assay from sample taken at screening visit -4

Exclusion criteria

Exclusion Criteria:

  • Systemic cyclosporine
  • History of PRCA or aplastic anemia
  • History of anti-EPO antibodies
  • Uncontrolled hypertension
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    1

    HX575, EPO Hexal

    Drug: HX575 solution for s.c. administration

Interventions

  • Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh

06

What researchers measure

Primary outcomes

  1. Change in hemoglobin level

    Time frame: 36 weeks

Secondary outcomes

  1. To document the safety and lack of immunogenicity of HX575. To determine the optimal dosing regimen of HX575 s.c. administration.

    Time frame: 36 weeks

07

Study locations

19 sites
  • MHAT "Dr. Tota Venkova"
    Gabrovo, 5300, Bulgaria
  • MHAT Pazardzhik
    Pazardzhik, 4400, Bulgaria
  • MHAT"Sveti Ivan Rilski"
    Sofia, 1431, Bulgaria
  • MHAT "Sveta Anna"
    Varna, 9000, Bulgaria
  • Polyclinique de Bordeaux-Nord
    Bordeaux, 33077, France
  • Centre Hospitalier Universitaire Limoges, Hôpital Dupuytren
    Limoges Cedex, 87042, France
  • KfH Nierenzentrum
    Bad König, 64732, Germany
  • KfH Nierenzentrum
    Berlin, 12045, Germany
  • Gemeinschaftspraxis Dr. Spitthöver, Dr. Knee, Dr. Gröschel
    Essen, 23538, Germany
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, 68309, Germany
  • Gesundheitszentrum Alzey Internistische Gemeinschaftspraxis
    Slzrx, 55232, Germany
  • Nierenzentrum Weinheim Kreiskrankenhaus Weinheim
    Weinheim, 69469, Germany
  • Spitalul Clinic de Nefrologie Dr. Carol Davila
    Bucuresti, 010731, Romania
  • Spitalul Universitar de Urgenta Bucuresti
    Bucuresti, 050098, Romania
  • Spitalul Judetean de Urgenta Deva
    Deva, 330084, Romania
  • Spitalul Clinic Municipal "Dr. Gavril Curteanu"
    Oradea, 410169, Romania
  • Spitalul Clinic Judetean Timisoara
    Timisoara, 300736, Romania
  • Hospital Universitario Puerta de Hierro
    Majadahonda, 28222, Spain
  • Hospital de Navarra
    Pamplona, 31008, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2009
First posted
Mar 26, 2009
Start
Apr 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Last update
Jun 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00869856
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Mar 26, 2009
Start date
Apr 2009
Primary completion
Aug 2009
Completion
Aug 2009
Last update
Jun 2, 2015

Study contacts

Karsten Roth
study chair · Hexal AG

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion